Biological Support
In-vitro Screening
Initial screening of bioactive ingredients using cell cultures to determine cytotoxicity and cellular uptake efficiency.
Clinical Trial
Double-blind, placebo-controlled studies on human volunteers to measure visible skin and hair improvements.
Dermatological Evaluation and Product Safety Test
Human Repeat Insult Patch Test (HRIPT) and Primary Irritation Patch Test (PIPT) on human volunteers, approved by Dermatologists.
Mechanism of Action: Bioépicrone™
Inhibition of Androgenic Alopecia (AGA)
Our latest study data confirms that Bioépicrone™ effectively downregulates SRD5A Type-2 by 22.9%. This enzymatic downregulation is critical in reducing the excessive conversion of testosterone to di-hydrotestosterone (DHT).
SRD5A2 (gene) - HFDPC (24hr)
Molecular Pathway Intervention
In-vitro Assessment of Bioépicrone™
Summary of efficacy data obtained from recent trials using human iPSC-derived models and HFDPC cultures.
| Study ID | Compound | Focus Area | Study Model | Results | Testing Facility |
|---|---|---|---|---|---|
| DC.760.09.032 | Bioépicrone™ 3% | Alopecia Areata | Human Follicle Dermal Papilla Cells (HFDPC) | Inhibition of Janus Kinase 3 (JAK3) by 43.1% | DermaclaimLab S.L., Valencia (España) |
| DC.760.09.032 | Bioépicrone™ 3% | Androgenic Alopecia | Human Follicle Dermal Papilla Cells (HFDPC) | Down-regulation of Steroid 5-alpha reductase type 2 (SRD5A2) by 22.9% | DermaclaimLab S.L., Valencia (España) |
| DC.618.13.057 | Bioépicrone™ 0.1% | Acne | Human iPSC-derived Sebocytes (PCI-SEB) | Down-regulation of Melanocortin 5 Receptor (MC5R) by 64.5% | DermaclaimLab S.L., Valencia (España) |
| DC.618.13.057 | Bioépicrone™ 0.1% | Acne | Human iPSC-derived Sebocytes (PCI-SEB) | Down-regulation of SRD5A1 by 14.9% | DermaclaimLab S.L., Valencia (España) |
Publications & White Papers
2024 Product Efficacy Report
Detailed analysis of our 2024 formulary updates.